Drugs / JNJ-38877605
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00651365 | Feb 2008 → Dec 2010 | neoplasm | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-38877605 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00651365 ↗ |
| Known as | JNJ-38877605-AAA | ChEMBL registry synonym — accepted as the source's own label CHEMBL2133806 ↗ |
| Action | Inhibit | “It is an inhibitor of mesenchymal epithelial transition (Met) kinase” NCT00651365 ↗ |
| Modality | Small molecule | — CHEMBL2133806 ↗ |
| Route | Oral | “JNJ-38877605 is provided in 10, 50, and 100 mg capsules for oral use.” NCT00651365 ↗ |
| Target | MET | “It is an inhibitor of mesenchymal epithelial transition (Met) kinase” NCT00651365 ↗ |